Search

Displaying results 6831 - 6840 of 10000 in total
  1. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  2. Drug

    Tirapazamine

    go.drugbank.com/drugs/DB04858
    Investigational

    Tirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. … This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia.

  3. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning

  4. Drug

    Darapladib

    go.drugbank.com/drugs/DB06311
    Investigational

  5. Drug

    Edotecarin

    go.drugbank.com/drugs/DB04882
    Investigational

    Edotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.

  6. Drug

    Biricodar

    go.drugbank.com/drugs/DB04851
    Investigational

    The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).

  7. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  8. Drug

    Ibopamine

    go.drugbank.com/drugs/DB13316
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Ocaperidone

    go.drugbank.com/drugs/DB06229
    Experimental

  10. Drug

    Inolimomab

    go.drugbank.com/drugs/DB15628
    Investigational

    Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease.